Tag Archives: analysts

Merck analysts to CEO: What’s so great about your pipeline beyond Keytruda?

Sales of Merck & Co.’s immuno-oncology heavy hitter Keytruda soared 66% in the fourth quarter to $ 2.15 billion, surpassing Wall Street’s expectations yet again. But Merck can’t rely solely on one blockbuster’s dutiful performance to drive sales and earnings growth going forward. Analysts’ worries about that fact only intensified on Friday after Merck put… Read More »

Can Amgen bone drug Evenity make a comeback? FDA, analysts aren't so sure

Amgen osteoporosis candidate Evenity (romosozumab) is trying to score an approval after cardiovascular red flags derailed it in mid-2017. But analysts aren’t so optimistic. The drug is slated to go before an FDA panel of experts later this week, but briefing documents from the FDA suggest that “risk for approval remains high and even if… Read More »